perfect- as i rather suspected. Looking at the slides featuring plots that list out the comparison studies virtually all those studies use chemo therapies that are either unheard of, not used in this cancer or just single gemcitabine alone!! So obviously panco with its use of background chemo known to be current best ( folfirox or gemcitanine plus abraxane) will show statistically better outcome. Doesn’t prove added benefit of device. If anything it could just point to confirming the better chemo used in panco really is better. Bizarre.
Ann: OncoSil AGM CEO Presentation, page-2
-
- There are more pages in this discussion • 108 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $13.32M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $23.68K | 4.971M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 23118264 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 5200224 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| OSL (ASX) Chart |